Biochemical Failure after Carbon Ion Radiotherapy for Prostate Cancer
Anticancer Research, 07/30/2012

1 Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Annals of Oncology, April 19, 2013    Clinical Article

2 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013

3 Gene-Environment Interactions in Bladder Cancer Cancer Research, April 1, 2013    Clinical Article

4 Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer Annual Review of Medicine, April 26, 2013    Review Article

5 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013    Clinical Article

6 The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies World Journal of Urology, April 2, 2013    Review Article    Clinical Article

7 Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer Current Opinion in Oncology, April 10, 2013    Review Article

8 Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma Urologic Oncology: Seminars and Original Investigations, April 1, 2013    Clinical Article

9 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, April 24, 2013    Clinical Article

10 Advances in bladder cancer imaging Full Text BMC Medicine, April 15, 2013    Free full text    Review Article    Clinical Article

11 Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer Cancer Causes and Control, April 8, 2013    Clinical Article

12 Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort European Journal of Cancer, March 22, 2013    Clinical Article

13 Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer Journal of the National Cancer Institute, April 11, 2013

14 Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria British Journal of Haematology, April 26, 2013

15 Low serum testosterone levels are predictive of prostate cancer World Journal of Urology, April 9, 2013    Clinical Article

16 Aberrant BAF57 Signaling Facilitates Pro-metastatic Phenotypes Clinical Cancer Research, April 1, 2013    Clinical Article

17 Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology, March 25, 2013    Clinical Article

18 Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09) The Lancet Oncology, March 7, 2013    Clinical Article

19 Urothelial carcinoma of the bladder and the upper tract: disparate twins The Journal of Urology, April 18, 2013    Review Article

20 A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Annals of Oncology, April 19, 2013    Clinical Article